|
|
|
| home > white papers > The Importance of ADCC in Assessing Clinically Relevant Differences - Sartorius Stedim BioOutsource Ltd |
|
|
 WHITE PAPERS |
|
|
Sartorius Stedim BioOutsource Ltd
|
|
The Importance of ADCC in Assessing Clinically Relevant Differences
|
|
Biosimilars have caused a revolution in the development of biologic
drugs. The model for biosimilars is a combination of speed to market and
low cost; these are fundamental to any biosimilar development project.
The biosimilars pathway to approval is not always without difficulty,
biosimilars are still relatively new, and as each new applicant is
reviewed we are learning more and more about these molecules.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
ACG Acquires Significant Stake in Mumbai-Based IQGEN-X
3 November 2020
The investment is aimed at augmenting R&D and IP in drug development.
The
funds infusion will enable IQGEN-X to fast-track research on existing
ANDAs and also setup a cGMP pilot facility in addition to the already
existing R&D facility.
More info >> |
|
 |
White Papers |
 |
|
Clinical Research in Spain
BioClever
This whitepaper is on clinical research in Spain, giving a general outline of the main characteristics of research in this country and an overview of the applicable regulations, along with the reasons why Spain is a good place to do research.
More info >> |
|
 |
Industry Events |
 |
DIA Europe 2021
15-19 March 2021, VIRTUAL CONFERENCE
DIA Europe is the must-attend event for all life science professionals
working in drug development, from discovery to marketed use. It
encourages open collaboration by bringing together representatives from
the entire spectrum of the life science landscape and facilitating
crucial discussions across several topic tracks: Clinical Development,
Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy,
and many more.
More info >> |
|
|
|
